This resolution expresses support for the Supreme Court's holding in Dobbs v. Jackson Women's Health Organization (that there is no constitutional right to abortion). The resolution also applauds the courage of the Justices for standing by their allegiance to the Constitution and the legitimacy of the Supreme Court, and it expresses a commitment to supporting policies that continue to protect all life.
The HEAL Act (HR 603) requires the U.S. Holocaust Memorial Museum Director to study how public elementary and secondary schools teach about the Holocaust and related antisemitism. The study will examine curriculum requirements, teaching methods (like project-based learning), instructional materials, and assessment approaches across states and school districts. It specifically analyzes whether Holocaust education is mandatory, optional, or integrated across subjects, and how schools address antisemitism and genocide prevention. The resulting report, due within 180 days of the study or three years after enactment, will inform Congress but does not change current school policies. This is a data-gathering measure, not a policy mandate.
This bill requires manufacturers of internet-connected toys (targeted at children) to clearly label packaging and include simple explanations in privacy terms about how personal data is collected, stored, and shared. Specifically, labels must state if the toy connects to the internet and collects children's information (like voice recordings or location), and privacy terms must detail what data is gathered, how it's used, and whether parents can disable data collection. It directly affects toy companies selling such products in the U.S. and is enforced by the FTC under existing laws for deceptive practices. The goal is to give parents clear, upfront information about data handling without restricting toy functionality.
Protecting Life and Integrity in Research Act of 2023 This bill restricts research that uses human fetal tissue from an induced abortion. Specifically, it prohibits the Department of Health and Human Services from conducting or supporting such research. Additionally, the bill applies requirements on the research of transplantation of fetal tissue for therapeutic purposes to research on fetal tissue in general. The bill also prohibits soliciting or acquiring a donation of human fetal tissue from an induced abortion, other than for purposes of an autopsy or burial.
This bill would prohibit the FDA from approving new abortion medications or investigational uses of existing ones. It would restrict currently approved abortion drugs to in-person administration only in clinics, hospitals, or medical offices by certified providers who can handle complications like ectopic pregnancy or severe bleeding. The law requires detailed adverse event reporting (excluding patient identifiers) to the FDA by both manufacturers and prescribers, and mandates provider certification covering pregnancy assessment, surgical intervention capabilities, and patient safety documentation. These provisions apply directly to healthcare providers, patients seeking medication abortions, and manufacturers of abortion drugs.
Protecting Life and Taxpayers Act of 2023 This bill requires federally funded entities to certify that they will not, subject to certain exceptions, perform abortions or provide funding to other entities that perform abortions. The bill provides exceptions for abortions (1) in cases of rape or incest; or (2) when the life of the woman is in danger due to a physical disorder, injury, or illness.
This bill nullifies certain changes made by the Food and Drug Administration (FDA) to dispensing requirements for mifepristone. (Mifepristone is a drug that is approved to end pregnancies through 10 weeks gestation when used in conjunction with the drug misoprostol. The procedure is often referred to as medication abortion or the abortion pill.) The FDA regulates the use of mifepristone through the Mifepristone Risk Evaluation and Mitigation Strategy (REMS) program. The program requires health care providers to comply with certain requirements in order to prescribe or dispense mifepristone to end a pregnancy; the program previously included an in-person dispensing requirement that required mifepristone to be directly dispensed to patients in clinics, medical offices, or hospitals. During the COVID-19 public health emergency, the FDA temporarily stopped enforcing the in-person dispensing requirement, which allowed mail-order pharmacies to fill and dispense mifepristone prescriptions. In January 2023, the FDA modified program requirements so as to (1) remove the in-person dispensing requirement, and (2) require pharmacies to be certified in the program in order to dispense mifepristone. The modifications allow retail pharmacies, after receiving certification, to dispense mifepristone pursuant to prescriptions that are written by program-certified prescribers. The bill nullifies the January 2023 changes and prohibits any similar changes in the future.
This bill prohibits federal funding to Planned Parenthood Federation of America and its affiliates for one year unless they certify they won't perform or fund abortions (with exceptions for rape/incest or life-threatening conditions). It redirects $235 million in existing funding to community health centers for women's health services like contraception, cancer screenings, and prenatal care. The bill explicitly states that redirected funds will continue to support all women's health services previously provided by Planned Parenthood. It also requires repayment of funds if Planned Parenthood violates the certification, and clarifies that overall federal funding for women's health services remains unchanged.
Protecting Life from Chemical Abortions Act This bill nullifies certain changes made by the Food and Drug Administration (FDA) to dispensing requirements for mifepristone. (Mifepristone is a drug that is approved to end pregnancies through 10 weeks gestation when used in conjunction with the drug misoprostol. The procedure is often referred to as medication abortion or the abortion pill.) The FDA regulates the use of mifepristone through the Mifepristone Risk Evaluation and Mitigation Strategy (REMS) program. The program requires health care providers to comply with certain requirements in order to prescribe or dispense mifepristone to end a pregnancy; the program previously included an in-person dispensing requirement that required mifepristone to be directly dispensed to patients in clinics, medical offices, or hospitals. During the COVID-19 public health emergency, the FDA temporarily stopped enforcing the in-person dispensing requirement, which allowed mail-order pharmacies to fill and dispense mifepristone prescriptions. In January 2023, the FDA modified program requirements so as to (1) remove the in-person dispensing requirement, and (2) require pharmacies to be certified in the program in order to dispense mifepristone. The modifications allow retail pharmacies, after receiving certification, to dispense mifepristone pursuant to prescriptions that are written by program-certified prescribers. The bill nullifies the January 2023 changes and prohibits the FDA from (1) exercising any enforcement discretion with respect to program requirements, or (2) reducing program protections until every state submits certain data regarding abortions to the Centers for Disease Control and Prevention. The bill also generally prohibits the declaration of a public health emergency with respect to abortions.
HCONRES 7 is a symbolic resolution passed by the U.S. House of Representatives that commends Iranian protesters - particularly women - who have risked safety to demonstrate against the Iranian regime's human rights abuses, including the mandatory hijab law and violent crackdowns following Mahsa Amini's death. It condemns the regime's use of violence (reportedly killing over 450 protesters) and detention of activists, while urging the Biden Administration to impose additional human rights sanctions on officials involved in repression and support internet freedom tools to bypass Iranian censorship. The resolution makes no binding policy changes but formally expresses congressional support for protesters' demands for freedom, justice, and an end to discriminatory laws targeting women. It does not directly affect any U.S. laws or policies but serves as a statement of U.S. position.
HJRES 22 disapproves a rule issued by the Department of Commerce that established procedures for temporarily suspending the payment of import duties under a specific presidential proclamation. The rule, published in the Federal Register (87 Fed. Reg. 56868), would have allowed delays in paying duties on certain imported goods. By passing this resolution, Congress nullifies the rule, preventing the Department of Commerce from enforcing it. This directly affects the Department's ability to manage duty suspensions for imports covered by the proclamation.
The Educational Choice for Children Act creates tax credits for individuals and corporations that contribute to scholarship organizations providing educational scholarships. Individuals can claim a credit up to 10% of their adjusted gross income or $5,000, while corporations can claim up to 5% of taxable income. Scholarships are available to students in households earning no more than 300% of the area median income and can be used for public or private school expenses, including religious schools. The bill establishes a $10 billion annual cap on total contributions with funds allocated on a first-come, first-served basis, and requires scholarship organizations to verify student income and distribute scholarships to multiple students. It also prohibits government control over scholarship organizations and schools, ensuring maximum freedom for these organizations.
